Fig. 3From: I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinomaSummary data from the baseline study in all patients receiving I-124 codrituzumab. VOIs were performed over the various organs and tissues. The amount of uptake was expressed in SUVmax or mean as indicated in the figure legend. The curves show that with the exception of the thyroid, which accumulates free I-124 over time, all other organs had a gradual decrease that was very similar to the clearance rate from the bloodBack to article page